Covered recipient · General Payments record
DAVID D WRIGHT
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$9,484.08
145 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,753.50 | 4 |
| Food and Beverage | $2,730.58 | 141 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID D WRIGHT
NPI 1699745638 · CMS profile ID 167264
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699745638?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699745638?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699745638?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 145 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1699745638?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
145 matching records · $9,484.08 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 145.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $85.00 | 09/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885761969 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $22.82 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890349971 | CMS |
| Celgene Corporation | $22.21 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541071 | CMS |
| Gilead Sciences, Inc. | $14.80 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929555731 | CMS |
| Novartis Pharmaceuticals Corporation | $20.16 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894457459 | CMS |
| Amgen Inc. | $18.63 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939819347 | CMS |
| Novartis Pharmaceuticals Corporation | $20.26 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894457461 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1.41 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541055 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.47 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541057 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $15.87 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929824221 | CMS |
| Celgene Corporation | $14.78 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541053 | CMS |
| Genentech USA, Inc. | $14.18 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950699455 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $20.07 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942300475 | CMS |
| Ipsen Biopharmaceuticals, Inc | $19.37 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893396579 | CMS |
| Gilead Sciences, Inc. | $20.98 | 08/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929555756 | CMS |
| Novartis Pharmaceuticals Corporation | $9.71 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894457457 | CMS |
| EISAI INC. | $21.90 | 07/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908030185 | CMS |
| ABBVIE INC. | $18.42 | 07/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893236107 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.62 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541051 | CMS |
| Novartis Pharmaceuticals Corporation | $14.82 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894457455 | CMS |
| PFIZER INC. | $14.86 | 07/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949197469 | CMS |
| ABBVIE INC. | $18.40 | 07/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893236105 | CMS |
| Gilead Sciences, Inc. | $19.77 | 07/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929555743 | CMS |
| Sobi, Inc | $12.41 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940369983 | CMS |
| Medtronic, Inc. | $21.45 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933517295 | CMS |
| Exelixis Inc. | $14.22 | 07/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932463587 | CMS |
| GlaxoSmithKline, LLC. | $26.72 | 07/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945075355 | CMS |
| Seagen Inc. | $17.02 | 07/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904114997 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.12 | 06/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920259411 | CMS |
| PFIZER INC. | $13.05 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949182413 | CMS |
| Novartis Pharmaceuticals Corporation | $24.16 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894457453 | CMS |
| Daiichi Sankyo Inc. | $26.12 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930846893 | CMS |
| Janssen Biotech, Inc. | $23.35 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885761987 | CMS |
| Janssen Biotech, Inc. | $0.63 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885761999 | CMS |
| Astellas Pharma US Inc | $17.00 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940207615 | CMS |
| Amgen Inc. | $21.35 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939819343 | CMS |
| Janssen Biotech, Inc. | $24.63 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885761993 | CMS |
| Lilly USA, LLC | $16.97 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917985293 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $23.15 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890349969 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,976.00 | 06/09/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932541031 | CMS |
| GE HealthCare | $16.30 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 953423293 | CMS |
| PFIZER INC. | $25.40 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949151873 | CMS |
| GENZYME CORPORATION | $21.71 | 06/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938873775 | CMS |
| Amgen Inc. | $16.27 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939164541 | CMS |
| AstraZeneca Pharmaceuticals LP | $9.47 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920250207 | CMS |
| Incyte Corporation | $18.04 | 05/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943021535 | CMS |
| Gilead Sciences, Inc. | $18.19 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929555735 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.14 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929809199 | CMS |
| EISAI INC. | $17.14 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908030189 | CMS |
| Lilly USA, LLC | $15.37 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918046317 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,446.88 | 2 |
| PY2025 | Principal investigator | $787,277.12 | 47 |
| PY2024 | Principal investigator | $547,309.75 | 19 |
| PY2023 | Principal investigator | $203,022.34 | 15 |
| PY2022 | Principal investigator | $391,313.17 | 29 |
| PY2021 | Principal investigator | $584,725.22 | 39 |
| PY2020 | Principal investigator | $429,379.09 | 39 |
| PY2019 | Principal investigator | $359,070.75 | 142 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
49 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,792.09 | 12/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185551062 |
| Principal investigator 1 | Genentech, Inc. | $54.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211652747 |
| Recipient | F. Hoffmann-La Roche AG | $862.55 | 12/10/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211535307 |
| Recipient | F. Hoffmann-La Roche AG | $584.33 | 12/08/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211535303 |
| Principal investigator 1 | AstraZeneca UK Limited | $500.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185551074 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228724800 |
| Principal investigator 1 | Genentech, Inc. | $688.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652577 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $937.73 | 11/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer | No dispute reported | 06/30/2026 | 1185551072 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228720459 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228728689 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228729263 |
| Principal investigator 1 | Genentech, Inc. | $15,158.00 | 10/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652504 |
| Principal investigator 1 | ABBVIE INC. | $6,143.88 | 09/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202510378 |
| Principal investigator 1 | ABBVIE INC. | $240.62 | 09/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202510288 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,691.00 | 08/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer | No dispute reported | 06/30/2026 | 1185551064 |
| Principal investigator 1 | Genentech, Inc. | $688.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651972 |
| Principal investigator 1 | Genentech, Inc. | $12,028.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652170 |
| Principal investigator 1 | ABBVIE INC. | $510.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202499382 |
| Principal investigator 1 | Genentech, Inc. | $6,014.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652095 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652260 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652278 |
| Principal investigator 1 | Genentech, Inc. | $688.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651891 |
| Principal investigator 1 | Genentech, Inc. | $15,408.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651869 |
| Principal investigator 1 | Genentech, Inc. | $155.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650962 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651236 |
| Principal investigator 1 | Genentech, Inc. | $313.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651288 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651396 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651416 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651420 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651474 |
| Principal investigator 1 | Genentech, Inc. | $155.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651575 |
| Principal investigator 1 | AstraZeneca UK Limited | $188,630.67 | 06/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185551066 |
| Principal investigator 1 | ABBVIE INC. | $510.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202485677 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $245,246.20 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185551068 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $250.92 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185551076 |
| Principal investigator 1 | Genentech, Inc. | $15,000.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650907 |
| Principal investigator 1 | Genentech, Inc. | $5,441.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651370 |
| Principal investigator 1 | ABBVIE INC. | $125.00 | 04/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202474499 |
| Principal investigator 1 | ABBVIE INC. | $510.00 | 04/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202474503 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651006 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651112 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651279 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651309 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651315 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651500 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,900.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Nave Subjec | No dispute reported | 06/30/2026 | 1235993793 |
| Principal investigator 1 | AstraZeneca UK Limited | $218,256.00 | 01/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185551060 |
| Principal investigator 1 | ABBVIE INC. | $534.38 | 01/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202437902 |
| Principal investigator 1 | AstraZeneca UK Limited | $2,474.13 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185551070 |